JP2023537229A - SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤 - Google Patents

SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤 Download PDF

Info

Publication number
JP2023537229A
JP2023537229A JP2023503508A JP2023503508A JP2023537229A JP 2023537229 A JP2023537229 A JP 2023537229A JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023537229 A JP2023537229 A JP 2023537229A
Authority
JP
Japan
Prior art keywords
cells
patient
enhancement
treated
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537229A5 (cg-RX-API-DMAC7.html
Inventor
マーチャント,シュリーマ
パテル,マニット
エレーヌ ダンカン,ロビン
フェルナンダ デ アンドラーデ フェルナンデス,マリア
アナント ジャダブ,ビシャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akseera Pharma Corp
Original Assignee
Akseera Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN2021/050325 external-priority patent/WO2021199078A2/en
Application filed by Akseera Pharma Corp filed Critical Akseera Pharma Corp
Publication of JP2023537229A publication Critical patent/JP2023537229A/ja
Publication of JP2023537229A5 publication Critical patent/JP2023537229A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023503508A 2020-07-18 2021-07-19 SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤 Pending JP2023537229A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN202021030633 2020-07-18
IN202021030633 2020-07-18
IN202021054151 2020-12-12
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.
INPCT/IN2021/050325 2021-03-30
PCT/IN2021/050699 WO2022018754A1 (en) 2020-07-18 2021-07-19 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (2)

Publication Number Publication Date
JP2023537229A true JP2023537229A (ja) 2023-08-31
JP2023537229A5 JP2023537229A5 (cg-RX-API-DMAC7.html) 2024-07-26

Family

ID=79728594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503508A Pending JP2023537229A (ja) 2020-07-18 2021-07-19 SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤

Country Status (7)

Country Link
US (1) US20240024337A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181917A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537229A (cg-RX-API-DMAC7.html)
AU (1) AU2021313476A1 (cg-RX-API-DMAC7.html)
CA (2) CA3179022A1 (cg-RX-API-DMAC7.html)
IL (1) IL300014A (cg-RX-API-DMAC7.html)
WO (1) WO2022018754A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115968375A (zh) * 2020-03-29 2023-04-14 阿克西拉制药公司 SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL316127A (en) * 2022-04-02 2024-12-01 Akseera Pharma Corp Enhancement of antiviral and anticancer therapies by combinations of poly(I:C) and cannabidiol.
WO2023195029A2 (en) * 2022-04-07 2023-10-12 Akseera Pharma Corp. A method of use for cannabidiol in the prevention and treatment of interferon-responsive conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010226604A1 (en) * 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
CN115968375A (zh) * 2020-03-29 2023-04-14 阿克西拉制药公司 SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂
WO2021209998A1 (en) * 2020-04-14 2021-10-21 Molad Ami Composition for the treatment of respiratory symptoms and methods thereof
AU2020447636A1 (en) * 2020-05-11 2022-12-08 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
WO2021231810A1 (en) * 2020-05-14 2021-11-18 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANIL, SEEGEHALLI M. ET AL.: "Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in l", SCIENTIFIC REPORTS, vol. 11(1), JPN6025031793, 14 January 2021 (2021-01-14), pages 1462, ISSN: 0005781477 *
BIORXIV [PREPRINT], JPN6025017903, 10 March 2021 (2021-03-10), pages 1 - 15, ISSN: 0005781474 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 177, JPN6025017908, 16 July 2020 (2020-07-16), pages 4967 - 4970, ISSN: 0005781476 *
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 168, JPN6025017905, 5 December 2020 (2020-12-05), pages 474 - 485, ISSN: 0005781475 *

Also Published As

Publication number Publication date
WO2022018754A1 (en) 2022-01-27
EP4181917A1 (en) 2023-05-24
CA3179022A1 (en) 2021-10-07
CA3189802A1 (en) 2022-01-27
EP4181917A4 (en) 2024-10-30
AU2021313476A1 (en) 2023-03-16
IL300014A (en) 2023-03-01
US20240024337A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US20240024337A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
US20240226120A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
Lee et al. Autophagic machinery activated by dengue virus enhances virus replication
JP2016041744A (ja) 抗ウイルス剤として用いられるmTORキナーゼ阻害剤
Meunier et al. A photoactivable natural product with broad antiviral activity against enveloped viruses, including highly pathogenic coronaviruses
CN113679726A (zh) 丹参提取物和醌类化合物在抗冠状病毒中的应用
Singh et al. Chloroquine: a potential drug in the COVID-19 scenario
TWI924879B (zh) 預防及治療嚴重特殊傳染性肺炎(covid-19)及長期性嚴重特殊傳染性肺炎(long covid)之方法及組合物
US10765664B2 (en) Treatment of infectious diseases
Jiang et al. Patchouli alcohol from Pogostemon cablin Benth inhibits H1N1 infection by repressing inflammasome and pyroptosis by targeting ubiquitin specific peptidase 18
Cursaro et al. A Focus on Natural Autophagy Modulators as Potential Host‐Directed Weapons Against Emerging and Re‐Emerging Viruses
Kandimalla et al. Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2
Jacolin et al. NAD metabolism plays multiple roles in influenza A virus replication in a novel ex vivo model of mouse lung infection
Mahajan et al. Recent Advancements in the Delivery of Therapeutic Agents Targeting RNA-dependent RNA Polymerase of SARS-CoV-2
Wang et al. Honokiol Inhibits Porcine Reproductive and Respiratory Syndrome Virus Proliferation by Targeting Viral RNA Polymerase
Tolulope Discovery of OJT009 as a Novel Inhibitor of Severe Acute Respiratory Syndrome Coronavirus 2 Infection for Potential Treatment of COVID-19
US20220323402A1 (en) Treatment, amelioration or prevention of a viral infection
TWI800146B (zh) 魚針草酸用於製備抑制新型冠狀病毒與變異株等感染與複製之醫藥組合物的用途
US20250325535A1 (en) IDENTIFICATION OF NOVEL SMALL-MOLECULE INHIBITORS OF SARS-CoV-2 BY CHEMICAL GENETICS
Zhang et al. A tetrazole-based immunomodulator confers mitochondrial protection and enhances host resistance against IHNV in rainbow trout
Khales et al. Amlodipine and diltiazem significantly repress human rotavirus infection in vitro
Lai et al. N-acylethanolamine acid amide hydrolase is a novel target for drugs against SARS-CoV-2 and Zika virus
RU2843665C1 (ru) Фармацевтическая композиция для профилактики или лечения эпидемического рнк-вирусного инфекционного заболевания
Chang Exploring the Blocking Capacity of Traditional Chinese Medicine on the Interaction Between Viral Spike Protein and Angiotensin Converting Enzyme II Using COVID-19 Pseudovirus System
Randhawa et al. Rappaport J and Gupta MK (2020) Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127